How CMMRD is diagnosed

A DNA sequencing method for primary blood cells using MSI detection and regression analysis effectively diagnoses CMMRD and MSI leukemia/lymphoma, addressing diagnostic challenges with high accuracy and enabling timely treatment.

JP7579798B2Active Publication Date: 2024-11-08INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021552168
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-06
Filing Date
2020-03-05
Publication Date
2024-11-08
Estimated Expiration
2040-03-05

AI Technical Summary

Technical Problem

Diagnosing CMMRD cancer or MSI leukemia/lymphoma is challenging due to the lack of clear clinical features and the presence of variants of unknown functional significance, making it difficult to differentiate from MSS cancer, which affects timely treatment and surveillance strategies.

Method used

A method involving DNA sequencing of primary blood cells to detect microsatellite instability (MSI) using massively parallel sequencing and a scoring system based on log10-transformed read counts and regression analysis to distinguish CMMRD from MSS, utilizing a model derived from MSS control subjects.

Benefits of technology

The method achieves 100% sensitivity and specificity in identifying CMMRD and MSI leukemia/lymphoma, enabling prompt diagnosis and personalized treatment strategies, and is faster than existing methods, with potential benefits from immune checkpoint inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579798000007
    Figure 0007579798000007
  • Figure 0007579798000008
    Figure 0007579798000008
  • Figure 0007579798000009
    Figure 0007579798000009
Patent Text Reader

Abstract

The present invention relates to the diagnosis of CMMRD. In this study, the inventors aimed to develop a test that can dramatically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massively parallel sequencing, they investigated the possibility that MSI, the main genomic and functional consequence of constitutive MMR deficiency, likely occurs in CMMRD PBCs long before any transformation. Thus, the present invention relates to a method for diagnosing CMMRD cancer or MSI leukemia / lymphoma in patients in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for diagnosing CMMRD cancer or MSI leukemia / lymphoma in a patient in need thereof.

[0002] Background technology: Lynch syndrome (LS) is an inherited cancer syndrome caused by heterozygous germline mutations in mismatch repair (MMR) genes (i.e., MLH1, MSH2, MSH6, or PMS2). Constitutional MMR deficiency (CMMRD) is a distinct and rare inherited cancer syndrome observed in patients with biallelic germline MMR pathogenic variants (Online Mendelian Inheritance in Man [OMIM] database accession no. 276300). Whereas most MMR-deficient (dMMR) cancers in LS patients occur in adulthood, CMMRD is characterized by the development of multiple MMR-deficient tumors in childhood, including early-onset colorectal cancer, lymphoma / leukemia, and brain tumors (1, 2). These tumors are usually highly aggressive, highlighting the need for rapid detection of CMMRD in order to adopt appropriate treatment and surveillance strategies for children with CMMRD and their families (3). As might be expected, the high mutational and neoantigen burden that characterizes MMR-deficient neoplasms has recently been associated with durable responses to immune checkpoint blockade in patients with CMMRD ( 4 , 5 ).

[0003] The diagnosis of CMMRD is challenging for several reasons. First, the tumors seen in this rare cancer syndrome are widespread and lack clear disease-specific clinical features. In this regard, we have recently proposed a scoring system to diagnose suspected CMMRD. 2 Second, variants of unknown functional significance (VUS) are detected in approximately 30% of patients, which makes the diagnosis uninformative (6).

[0004] Summary of the invention: In this study, we aimed to develop a test that could dramatically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massively parallel sequencing, we investigated the possibility that MSI, the main genomic and functional consequence of constitutive MMR deficiency, likely occurs in CMMRD PBCs long before any transformation.

[0005] Thus, the present invention relates to a method for diagnosing CMMRD cancer or MSI leukemia / lymphoma in a patient in need thereof. In particular, the present invention is defined by its claims.

[0006] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A first aspect of the present invention is a method of diagnosing CMMRD cancer or MSI leukemia / lymphoma in a patient in need thereof, comprising: i) extracting DNA from a sample obtained from the patient; ii) sequencing a number (N) of repeat sequences having a length of (x) nucleic acids from the patient's DNA; iii) repeating steps i) and ii) for at least one control subject with stable microsatellite cancer (MSS control subject); iv) for the patient and MSS control subjects, log10 transforming the read counts per locus and for each repeat obtained from the MSS control subject, performing limit regression; and v) determining the sequence of repeats obtained from the patient and MSS control subjects using the following formula: [ka] where N=maximum number of sequenced repeats; n=number of repeat sequences, Δ=number of reads (sample of patient in need thereof)-number of reads (limit regression from MSS control subjects) to obtain an ms. score; vi) comparing the ms. score obtained for the patient in need thereof with the ms. score of the MSS control subjects; and vii) concluding that the patient in need thereof has a CMMRD cancer or an MSI leukemia / lymphoma if the ms. score of the patient in need thereof exceeds the ms. score of the MSS control subject.

[0007] As used herein, limit regression is used herein for calibration / referencing of the tested patients. According to the present invention, limit regression of each repeat obtained from the MSS control subjects is performed by determining the lowest correlation coefficient and regression slope.

[0008] According to the invention, the limit regression obtained for each repeat obtained from the MSS control subjects is used as a model to predict the log10 transformed read count that a patient will exceed if he or she has CMMRD or MSI leukemia / lymphoma. According to the invention, if more than one MSS control subject is used, the limit regression obtained is a global limit regression for all MSS control subjects.

[0009] Thus, when using this method (log10 for all samples (patients and MSS controls) and limit regression for MSS controls), and when the ms. scores of patient and MSS control subjects are rescaled to the highest ms. score of the MSS controls, if the patient has CMMRD or MSI leukemia / lymphoma the ms. score will be above 1 (see, e.g., Figure 2).

[0010] Accordingly, another embodiment of the present invention is a method of diagnosing CMMRD cancer or MSI leukemia / lymphoma in a patient in need thereof, comprising: i) extracting DNA from a sample obtained from the patient; ii) sequencing a number (N) of repeat sequences having a length of (x) nucleic acids from the patient's DNA; iii) repeating steps i) and ii) for at least one MSS control subject; iv) loglO transforming the read counts per locus for the patient and for each repeat obtained from the MSS control subject, loglO transforming the read counts per locus and performing limit regression; and v) calculating the following formula: [ka] where N=maximum number of sequenced repeats; n=number of repeat sequences, Δ=number of reads (sample of patient in need thereof)-number of reads (limit regression from MSS control subjects) to obtain an ms. score; vi) comparing the ms. score obtained for the patient in need thereof with the ms. score of the MSS control subjects; and vii) concluding that the patient in need thereof has a CMMRD cancer or an MSI leukemia / lymphoma if the ms. score of the patient in need thereof exceeds the ms. score of the MSS control subject.

[0011] Thus, yet another embodiment of the present invention is a method of diagnosing CMMRD cancer or MSI leukemia / lymphoma in a patient in need thereof, comprising: i) extracting DNA from a sample obtained from the patient; ii) sequencing a number (N) of repeat sequences having a length of (x) nucleic acids from the patient's DNA; iii) repeating steps i) and ii) for at least one MSS control subject; iv) performing extreme regression by log10 transforming the read counts per locus for the patient and for each repeat obtained from the MSS control subject, log10 transforming the read counts per locus and finding the lowest correlation coefficient and regression slope and using this extreme regression as a model to predict the log10 transformed read count that the patient will exceed if they have CMMRD or MSI leukemia / lymphoma; and v) using the following formula: [ka] where N=maximum number of repeats sequenced; n=number of repeat sequences, and Δ=number of reads (sample of patient in need thereof)-number of reads (marginal regression from MSS control subjects); vi) comparing the ms. score obtained for the patient in need thereof with the ms. score of the MSS control subjects; and vii) concluding that the patient in need thereof has a CMMRD cancer if the ms. score of the patient in need thereof exceeds the ms. score of the MSS control subjects.

[0012] As used herein, the term "CMMRD" for "constitutional mismatch repair deficiency" refers to an inherited cancer predisposition that typically exists during infancy, childhood, or young adulthood. Individuals with CMMRD are at risk for developing hematological malignancies, brain tumors, colon, small intestine, uterine, gastric, urinary, and other types of cancer. Individuals with CMMRD are estimated to have a 16-fold higher risk than those with biallelic MSH2 mutations. The individual may be diagnosed with these cancers multiple times throughout their life. Additionally, "cafe au lait" spots have been reported in these individuals. CMMRD is caused by mutations in the mismatch repair (MMR) genes: MLH1, MSH2, MSH6, and PMS2. If a person has one mutation in one of the MMR genes, they have Lynch syndrome. To develop CMMRD, a person must have two genetic mutations in the same MMR gene.

[0013] As used herein, the term "MSI cancer" means that instability is detected at at least two microsatellite markers. In contrast, if instability is detected at only one microsatellite marker or none at all, the cancer is "MSS cancer". This definition is only valid when the diagnosis is made by pentaplex method (see, for example, Suraweera N et al., Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002 or Buhard O et al., Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol.2006). "MSS cancer" means cancer with stable microsatellites. "MSI cancer" refers to cancer with unstable microsatellites.

[0014] As used herein, the term "repeat" refers to the number of nucleic acids (or nucleobases) that are repeated at a particular locus. Thus, the term "repeat" refers to the length of a nucleic acid. For example, if the repeat for nucleic acid A is 12, this means that nucleic acid A is repeated 12 times consecutively at a particular locus. According to the present invention, as used herein, the term "repeat" has the same meaning as "microsatellite".

[0015] As used herein, the terms "number of repeats" or "reads" refer to Number of " refers to the number of times a "repeat" of a particular length (e.g., 12 nucleic acid A's) is repeated for a particular locus. Thus, "number of repeats" also refers to the number of loci that contain a given repeat.

[0016] As used, the term "read" refers to a DNA fragment generated by a sequencer instrument that is an exact copy of the locus being sequenced and is used to determine its nucleic acid content and sequence order.

[0017] As used herein, the term "N" refers to the maximum number of repeats in one particular sequencing assay, which also corresponds to the number of loci examined.

[0018] As used herein, the term "sample" refers to a sample of DNA, particularly germ cells It refers to any biological sample obtained from a subject that is prone to contain DNA. Typically, the sample includes, but is not limited to, a bodily fluid sample, such as blood, plasma, or serum. In certain embodiments, the sample is a peripheral blood mononuclear cell (PBMC), a primary blood cell (PBC), or a tumor circulating lymphoid cell. In certain embodiments, the sample is obtained from a PBMC or a PBC. germ cells The DNA is used to diagnose CMMRD. In certain embodiments, the present invention is also useful for diagnosing MSI leukemia / lymphoma, where the sample is cancerous circulating lymphoid cells, and where the DNA from these cancerous cells is sequenced.

[0019] As used herein, the term "MSI leukemia / lymphoma" refers to all leukemias and lymphomas that have microsatellite instability.

[0020] As used herein, the term "patient" refers to a mammal. Typically, a patient according to the present invention refers to any subject, preferably a human, suffering from a CMMRD cancer or an MSI leukemia / lymphoma cancer. Also, the term "MSS control subject" refers to a subject having an MSS cancer. According to the present invention, the number of MSS control subjects used may be 1 to 30 or more. Thus, several MSS control subjects can be used to perform limit regression according to the method of the present invention.

[0021] As used herein, the term "nucleic acid" or "nucleobase" has its general meaning in the art and refers to coding or non-coding nucleic acid sequences. Nucleic acids include DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) nucleic acids. Thus, examples of nucleic acids include, but are not limited to, DNA, mRNA, tRNA, rRNA, tmRNA, miRNA, piRNA, snoRNA, and snRNA. Thus, nucleic acids encompass coding and non-coding regions of a genome (i.e., nuclear or mitochondrial).

[0022] In a particular embodiment, sequencing according to the invention is performed for a number of loci between 10 and 10,000, in particular between 100 and 10,000, more particularly between 100 and 1,000.

[0023] In certain embodiments, the read count per locus after sequencing is 500-4000, specifically 1000-4000, specifically 1000-3000, more specifically 1500-2500.

[0024] In a particular embodiment, the length (x) (or number) of the nucleic acid in the particular repeat is between 8 and 30, particularly between 8 and 14. According to the invention, the length (x) (or number) of the nucleic acid in the particular repeat may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.

[0025] As used herein, the term "cancer" has its general meaning in the art and includes, but is not limited to, solid tumors and blood-borne tumors. The term cancer includes diseases of the skin, tissues, organs, bone, cartilage, blood, and blood vessels. The term "cancer" further encompasses both primary and metastatic cancers. Examples of cancers include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gums, head, kidney, liver, lung, nasopharynx, cervix, ovary, prostate, skin, stomach, testes, tongue, or uterus. Furthermore, the cancer may be specifically of the following histological types, but is not limited to: malignant neoplasm; carcinoma; undifferentiated carcinoma; giant cell and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; piloma; transitional cell carcinoma; papillary transitional cell carcinoma; adenoma; malignant gastrinoma; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular and cholangiocarcinoma; trabecular adenoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyps; familial adenomatous polyposis of the colon;solid carcinoma;malignant carcinoid tumor;bronchoalveolar adenocarcinoma;papillary adenocarcinoma;chromophobe carcinoma;eosinophilic carcinoma;eosinophilic adenoma;basophilic adenocarcinoma;clear cell adenocarcinoma;granular cell carcinoma;follicular adenocarcinoma;papillary and follicular adenocarcinoma;non-encapsulating sclerosing carcinoma;adrenal cortical carcinoma;endometrial carcinoma;skin adnexal carcinoma;apocrine gland carcinoma;sebaceous gland carcinoma;ear canal adenocarcinoma;mucoepidermoid carcinoma;cystadenocarcinoma;papillary cystadenocarcinoma;papillary serous cystadenocarcinoma; Mucinous cystadenocarcinoma;Mucinous adenocarcinoma;Signet ring cell carcinoma;Invasive ductal carcinoma;Medullary carcinoma;Lobular carcinoma;Inflammatory carcinoma;Paget's disease of the breast;Acinic cell carcinoma;Adenosquamous carcinoma;Adenocarcinoma with squamous metaplasia;Malignant thymoma;Malignant ovarian stromal tumor;Malignant thecal tumor;Malignant granulosa cell tumor;Malignant loblastoma;Sertoli cell carcinoma;Malignant Leydig cell tumor;Malignant lipid cell tumor;Malignant paraganglioma;Malignant extramammary paraganglioma;Pheochromocytoma;Hemangiocytic angiosarcoma ;Malignant melanoma;Amelanotic melanoma;Superficial spreading melanoma;Malignant melanoma in giant pigmented nevus;Epithelioid cell melanoma;Malignant blue nevus;Sarcoma;Fibrosarcoma;Malignant fibrous histiocytoma;Myxosarcoma;Liposarcoma;Leiomyosarcoma;Rhabdomyosarcoma;Embryonic rhabdomyosarcoma;Alveolar rhabdomyosarcoma;Stroma sarcoma;Malignant mixed tumor;Müllerian mixed tumor;Nephroblastoma;Hepatoblastoma;Carcinosarcoma;Malignant mesenchymoma;Malignant Brenner tumor;Malignant phyllodes tumor;Synovial sarcoma;Malignant mesothelioma;Dysgerminoma;Embryonal carcinoma;Malignant teratoma;Malignant ovarian thyroid tumor;Choriocarcinoma;Malignant mesonephroma;Angiosarcoma;Malignant hemangioendothelioma;Kaposi's sarcoma;Malignant hemangiopericytoma;Lymphangiosarcoma;Osteosarcoma;Parosteal osteosarcoma;Chondrosarcoma;Malignant chondroblastoma;Mesenchymal chondrosarcoma;Giant cell tumor of bone;Ewing's sarcoma;Malignant odontogenic tumor;Ameloblastoma;Malignant ameloblastoma;Ameloblastic fibrosarcoma;Malignant pinealoma;Chordoma;Malignant glioma;Ependymoma;Astrocytoma;Protoplasmic astrocytoma;Fibrous astrocytoma;Astroblastoma;Glioblastoma;Oligodendroglioma;Oligodendroglioma;Primitive neuroectodermal;Cerebellar sarcoma;Ganglioblastoma;Neuroblastoma;Retinoblastoma tumor; olfactory neurogenic tumor; malignant meningioma; neurofibrosarcoma; malignant neurilemmoma; malignant granular cell tumor; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; lateral granuloma; small lymphocytic lymphoma; large cell, diffuse malignant lymphoma; malignant follicular lymphoma; mycosis fungoides; other specified non-Hodgkin's lymphoma; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphocytic leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophil leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. In some embodiments, the subject is afflicted with colorectal cancer, more particularly metastatic colorectal cancer;

[0026] In a particular embodiment, the cancer is colorectal cancer, and thus CMMRD colorectal cancer.

[0027] In one embodiment, the method of the invention may further include the step of viii) communicating the results to the patient.

[0028] In certain embodiments, the above methods allow for distinguishing MSS cancers from CMMRD cancers.

[0029] The ms. score of the present invention can be implemented by one or more programmable processors that execute one or more computer programs to perform functions by manipulating input data and producing output. The algorithms can also be implemented in a device as dedicated logic circuits, such as, for example, FPGAs (field programmable gate arrays) or ASICs (application specific integrated circuits). Processors suitable for executing computer programs include, by way of example, general purpose and dedicated microprocessors, as well as any one or more processors of any type of digital computer. Generally, a processor receives instructions and data from a read-only memory or a random access memory, or both. The essential elements of a computer are a processor for executing instructions, and one or more memory devices for storing instructions and data. Generally, a computer includes one or more mass storage devices, such as magnetic, magneto-optical, or optical disks, for storing data, or is operatively connected to receive data from or transfer data to the device, or both. However, a computer need not have such devices. Furthermore, a computer may be incorporated in another device. Computer-readable media suitable for storing computer program instructions and data include all forms of non-volatile memory, media, and memory devices, including, by way of example, semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks, such as internal hard disks or removable disks; magneto-optical disks; and disks such as CD-ROM and DVD-ROM. The processor and memory may be supplemented by, or incorporated into, dedicated logic circuitry. To provide for interaction with a user, embodiments of the present invention may be implemented on a computer that includes a display device for displaying information to a user, such as, in non-limiting examples, a CRT (cathode ray tube) or LCD (liquid crystal display) monitor, as well as a keyboard and a pointing device, such as a mouse or trackball, by which a user can provide input to the computer.Moreover, other types of devices may be used to provide interaction with the user; for example, feedback provided to the user may be any form of sensory feedback, such as visual feedback, auditory feedback, or haptic feedback; and input from the user may be received in any form, including audio, speech, or tactile input. Thus, in some embodiments, the algorithm may be executed in a computing system that includes a back-end component, such as a data server, or includes a middleware component, such as an application server, or includes a front-end component, such as a client computer having a graphical user interface or a web browser through which a user may interact with an implementation of the invention, or includes any combination of one or more such back-end, middleware, or front-end components. The components of the system may be interconnected by any form or medium of digital data communication, such as a communications network. Examples of communications networks include local area networks ("LANs") and wide area networks ("WANs"), such as the Internet. The computing system may include clients and servers. The clients and servers are generally remote from each other and typically interact through a communications network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.

[0030] Sequencing Method: According to the present invention, the sequencing step can be performed by any method, including, but not limited to, chemical sequencing using the Maxam-Gilbert method (Methods in Enzymology 65, 499-560 (1980)); enzymatic sequencing using the Sanger method Proc. Natl. Acad. Sci. USA 74, 5463-67 (1977)); sequencing by mass spectrometry; sequencing using chip-based technologies; and real-time quantitative PCR.

[0031] In chemical sequencing, base-specific modification results in base-specific cleavage of radioactively or fluorescently labeled DNA fragments. Four separate base-specific cleavage reactions generate four sets of nested fragments, which are separated according to length by polyacrylamide gel electrophoresis (PAGE). After autoradiography, each band (fragment) in the gel originates from a base-specific cleavage event, and the sequence can be read directly. Thus, the lengths of the fragments in the four "ladders" correspond directly to specific positions in the DNA sequence.

[0032] Enzymatic sequencing starts with a primer / template system, extends the primer into the region of unknown DNA sequence, thereby copying the template, and forms a set of four base-specific DNA fragments by synthesizing complementary strands with a DNA polymerase, e.g., the Klenow fragment of E. coli DNA polymerase I, DNA polymerase from Thermus aquaticus, Taq DNA polymerase, or modified T7 DNA polymerase, Sequenase (Tabor et al, Proc. Natl. Acad. Scl. USA 84, 4767-4771 (1987)), in the presence of a chain-terminating agent.

[0033] In the mid-to-late 1990s, several novel methods for DNA sequencing (high-throughput sequencing (HTS) methods) were developed and incorporated into commercially available DNA sequencers by 2000. Collectively, these are referred to as "next-generation" or "second-generation" sequencing methods. These HTS methods included, but were not limited to: single-molecule real-time sequencing, ion semiconductor, pyrosequencing, sequencing-by-synthesis, sequencing-by-ligation, nanopore sequencing, chain termination, and sequencing-by-hybridization. Some of these methods are capable of whole-gene sequencing (WGS), whole-exome sequencing (WES), or targeted sequencing.

[0034] In a particular embodiment, the sequencing according to the methods of the invention is ultra-deep sequencing, such as second generation sequencing (NGS), performed using a targeted massively parallel sequencing approach, with which a designated panel of regions in the genome, herein mononucleoid microsatellites, are sequenced (see, e.g., Goodwin, S and all, 2016. Coming of age: Ten years of next-generation sequencing technologies. Nature Reviews Genetics).

[0035] Treatment Method In another embodiment, the present invention also relates to a method of treating cancer in a patient identified as having a CMMRD or MSI leukemia / lymphoma cancer according to the methods of the present invention, comprising treating the patient with radiation therapy, chemotherapy, immunotherapy, or a combination thereof.

[0036] The term "chemotherapeutic agent" refers to a chemical compound that is effective in inhibiting tumor growth. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelanamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelamine; acetogenins (particularly bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; kallistatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); cryptophycins (particularly cryptophycin 1 and cryptophycin 2). 8); dolastatins; duocarmycins (including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatins; nitrogen mustards such as chlorambucil, chlornaphazine, colofosfamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembitine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as enediyne antibiotics (e.g., calicheamicin (11 and calicheamicin 211, e.g., Agnew, See Chem Intl. Ed. Engl. 33:183-186 (1994); the dynemicins, including dynemicin A; the esperamicins;Also included are neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potofilomycin, puromycin, keramycin, rodorubicin, antimetabolites such as streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; antiadrenal agents such as aminoglutethimide, mitotane, trilostane; frolinic acid folic acid supplements such as aceglatone, aldophosphamide glycosides, aminolevulinic acid, amsacrine, bestravcil, bisantrene, edatrexate, defofamine, demecolcine, diazicon, elformitin, elliptinium acetate, epothilone, etoglucide, gallium nitrate, hydroxyurea, lentinan, lonidynin, maytansinoids such as maytansine and ansamitocin, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllic acid, 2-ethylhydrazide, procarbazine, PSK (registered trademark), razoxane, rhizoxin, schizofuran, spirogermanium, tenuazonic acid;triazicon; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veraculin A, roridin A, and anguidine); urethanes; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids such as paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronic acid; CPT-1 1; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids, or derivatives of any of the above. Also included within this definition are antihormonal agents that act to modulate or inhibit the action of hormones on tumors, e.g., antiestrogens, including tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxyphene, ketoxifene, LY117018, onapristone, and toremifene (Fareston); and antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids, or derivatives of any of the above;

[0037] If it is concluded that the subject has a CMMRD cancer, the physician may choose to treat the patient with a targeted therapy.

[0038] Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") involved in cancer growth, progression, and spread. Targeted cancer therapies are sometimes called "molecularly targeted drugs," "molecularly targeted therapies," "precision medicine," or similar names.

[0039] In some embodiments, the targeted therapy comprises administering a tyrosine kinase inhibitor to the subject. The term "tyrosine kinase inhibitor" refers to any of a variety of treatments or drugs that act as selective or non-selective inhibitors of receptor and / or non-receptor tyrosine kinases. Tyrosine kinase inhibitors and related compounds are well known in the art and are described in U.S. Patent Publication No. 2007 / 0254295, which is incorporated herein by reference in its entirety. Those skilled in the art will appreciate that compounds related to tyrosine kinase inhibitors will reproduce the effects of tyrosine kinase inhibitors, e.g., related compounds will act on different members of the tyrosine kinase signaling pathway to produce the same effect as a tyrosine kinase inhibitor of that tyrosine kinase. Examples of tyrosine kinase inhibitors and related compounds suitable for use in the methods of the present invention include dasatinib (BMS-354825), PP2, BEZ235, saracatinib, gefitinib (Iressa), sunitinib (Sutent; SU11248), erlotinib (Tarceva; OSI-1774), lapatinib (GW572016; GW2016), canertinib (CI 1033), semaxinib (SU5416), vatalanib (PTK787 / ZK222584), sorafenib (BAY 43-9006), imatinib (Gleevec; STI571), leflunomide (SU101), vandetanib (Zactima; ZD6474), MK-2206 (8-[4-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one hydrochloride), derivatives thereof, analogs thereof, and combinations thereof.Additional tyrosine kinase inhibitors and related compounds suitable for use in the present invention are described in, for example, U.S. Patent Publication No. 2007 / 0254295, U.S. Patent Nos. 5,618,829, 5,639,757, 5,728,868, 5,804,396, 6,100,254, 6,127,374, 6,245,759, 6,306,874, 6,313,138, 6,316,444, 6,329,380, Nos. 6,344,459, 6,420,382, 6,479,512, 6,498,165, 6,544,988, 6,562,818, 6,586,423, 6,586,424, 6,740,665, 6,794,393, 6,875,767, 6,927,293, and 6,958,340, all of which are incorporated herein by reference in their entireties. In certain embodiments, the tyrosine kinase inhibitor is orally administered and is a small molecule kinase inhibitor that has been the subject of at least one Phase I clinical trial, more preferably at least one Phase II clinical trial, even more preferably at least one Phase III clinical trial, and most preferably is approved by the FDA for at least one hematological or oncological indication.Examples of such inhibitors include gefitinib, erlotinib, lapatinib, canertinib, BMS-599626 (AC-480), neratinib, KRN-633, CEP-11981, imatinib, nilotinib, dasatinib, AZM-475271, CP-724714, TAK-165, sunitinib, vatalanib, CP-547632, vandetanib, bosutinib, lestaurtinib, tanzutinib, midostaurin, enzastaurin, AEE-788, pazopanib, These include, but are not limited to, cecitabine, axitinib, motasenib, OSI-930, cediranib, KRN-951, dovitinib, seliciclib, SNS-032, PD-0332991, MKC-I (Ro-317453; R-440), sorafenib, ABT-869, brivanib (BMS-582664), SU-14813, telatinib, SU-6668, (TSU-68), L-21649, MLN-8054, AEW-541, and PD-0325901.

[0040] If it is concluded that the subject has a CMMRD cancer, the physician may choose to administer an immunotherapeutic agent to the subject.

[0041] The term "immunotherapeutic agent" as used herein refers to a compound, composition, or treatment that indirectly or directly enhances, stimulates, or increases the body's immune response to cancer cells and / or reduces the side effects of other anti-cancer therapies. Thus, immunotherapy is a therapy that directly or indirectly stimulates or enhances the immune system's response to cancer cells and / or reduces the side effects that may be caused by other anti-cancer drugs. Immunotherapy is also referred to in the art as immunological therapy, biological therapy, biological response modifier therapy, and biotherapy. Examples of common immunotherapeutic agents known in the art include, but are not limited to, cytokines, cancer vaccines, monoclonal antibodies, and non-cytokine adjuvants. Alternatively, immunotherapy treatment may consist of administering a certain amount of immune cells (T cells, NK cells, dendritic cells, B cells...) to the subject.

[0042] Immunotherapeutic agents may be non-specific, i.e., broadly boosting the immune system so that the human body is more effective at fighting the growth and / or spread of cancer cells, or may be specific, i.e., targeting the cancer cells themselves, and immunotherapy regimens may combine the use of both non-specific and specific immunotherapeutic agents.

[0043] Non-specific immunotherapeutic agents are substances that stimulate or indirectly improve the immune system. Non-specific immunotherapeutic agents have been used alone as the main therapy for treating cancer, and in addition to the main therapy, in this case, non-specific immunotherapeutic agents also function as adjuvants to enhance the effectiveness of other therapies (e.g., cancer vaccines). In this latter situation, non-specific immunotherapeutic agents can also function to reduce the side effects of other therapies, such as bone marrow suppression induced by certain chemotherapeutic agents. Non-specific immunotherapeutic agents can act on key immune system cells and cause secondary responses, such as increased production of cytokines and immunoglobulins. Alternatively, the agent itself may contain cytokines. Non-specific immunotherapeutic agents are generally classified as cytokine or non-cytokine adjuvants.

[0044] A number of cytokines are utilized in the treatment of cancer, either as general non-specific immunotherapy designed to boost the immune system or as adjuvants provided with other therapies. Suitable cytokines include, but are not limited to, interferons, interleukins, and colony stimulating factors.

[0045] Interferons (IFNs) contemplated by the present invention include the general types of IFNs IFN-alpha (IFN-a), IFN-beta (IFN-beta), and IFN-gamma (IFN-y). IFNs can act directly on cancer cells, for example, by slowing down their proliferation, promoting their development into cells with more normal behavior, and / or increasing the production of antigens, thereby making it easier for the immune system to recognize and destroy the cancer cells. IFNs can also act indirectly on cancer cells, for example, by slowing down angiogenesis, enhancing the immune system, and / or stimulating natural killer (NK) cells, T cells, and macrophages. Recombinant IFN-alpha is commercially available as Roferon (Roche Pharmaceuticals) and Intron A (Schering Corporation). IFN-alpha, used alone or in combination with other immunotherapeutic or chemotherapeutic agents, has shown effectiveness in the treatment of a variety of cancers, including melanoma (including metastatic melanoma), renal cancer (including metastatic renal cancer), breast cancer, prostate cancer, and cervical cancer (including metastatic cervical cancer).

[0046] Interleukins contemplated by the present invention include IL-2, IL-4, IL-11, and IL-12. Examples of commercially available recombinant interleukins include Proleukin® (IL-2; Chiron Corporation) and Neumega® (IL-12; Wyeth Pharmaceuticals). Zymogenetics, Inc. (Seattle, Wash.) is currently testing a recombinant form of IL-21, which is also contemplated for use in the combination of the present invention. Interleukins, alone or in combination with other immunotherapeutic or chemotherapeutic agents, have shown efficacy in the treatment of a variety of cancers, including renal cancer (including metastatic renal cancer), melanoma (including metastatic melanoma), ovarian cancer (including recurrent ovarian cancer), cervical cancer (including metastatic cervical cancer), breast cancer, colorectal cancer, lung cancer, brain cancer, and prostate cancer.

[0047] Interleukins have also shown good activity in combination with IFN-alpha in the treatment of various cancers (Negrier et al., Ann Oncol. 2002 13(9):1460-8; Touranietal, J. Clin. Oncol. 2003 21(21):398794).

[0048] Colony stimulating factors (CSFs) contemplated by the present invention include granulocyte colony stimulating factor (G-CSF or filgrastim), granulocyte-macrophage colony stimulating factor (GM-CSF or sargramostim), and erythropoietin (epoetin alfa, darbepoietin). Treatment with one or more growth factors can help stimulate the production of new blood cells in subjects undergoing conventional chemotherapy. Thus, treatment with CSFs can be useful in reducing chemotherapy-related side effects and can allow the use of higher doses of chemotherapy agents. Various recombinant colony stimulating factors are commercially available, such as Neupogen® (G-CSF; Amgen), Neulasta (pegfilgrastim; Amgen), Leukine (GM-CSF; Berlex), Procrit (erythropoietin; Ortho Biotech), Epogen (erythropoietin; Amgen), Arnesp (erythropoietin). Colony stimulating factors have shown efficacy in the treatment of cancers, including melanoma, colorectal cancer (including metastatic colorectal cancer), and lung cancer.

[0049] Suitable non-cytokine adjuvants for use in the combinations of the present invention include, but are not limited to, levamisole, aluminum hydroxide (alum), bacillus Calmette-Guerin (ACG), incomplete Freund's adjuvant (IFA), QS-21, DETOX, keyhole limpet hemocyanin (KLH), and dinitrophenyl phosphate (DNP). Non-cytokine adjuvants in combination with other immunological and / or chemotherapeutic agents have demonstrated efficacy against a variety of cancers, including, for example, colon and colorectal cancer (levimazole); melanoma (BCG and QS-21); and renal and bladder cancer (BCG).

[0050] In addition to having a specific or non-specific target, immunotherapeutics may be active, i.e., they may stimulate the body's own immune response, or they may be passive, i.e., they may involve components of the immune system generated outside the body.

[0051] Passive specific immunotherapy typically involves the use of one or more monoclonal antibodies that are specific for a particular antigen found on the surface of cancer cells or that are specific for a particular cell growth factor. Monoclonal antibodies can be used in the treatment of cancer in a number of ways, for example, by enhancing the subject's immune response to a particular type of cancer, by interfering with the proliferation of cancer cells by targeting a particular cell growth factor, such as those involved in angiogenesis, or by enhancing the delivery of other anti-cancer agents to cancer cells when linked or conjugated to agents such as chemotherapeutic agents, radioactive particles, or toxins.

[0052] Monoclonal antibodies currently used as cancer immunotherapeutics suitable for inclusion in the combinations of the present invention include, but are not limited to, rituximab (Rituxan®), trastuzumab (Herceptin®), ibritumomab tiuxetan (Zevalin®), tositumomab (Bexxar®), cetuximab (C-225, Erbitux®), bevacizumab (Avastin®), gemtuzumab ozogamicin (Mylotarg®), alemtuzumab (Campas®), and BL22. Monoclonal antibodies are used to treat a wide range of cancers, including breast cancer (including advanced metastatic breast cancer), colorectal cancer (including advanced and / or metastatic colorectal cancer), ovarian cancer, lung cancer, prostate cancer, cervical cancer, melanoma, and brain cancer. Other examples include an anti-CTLA4 antibody (e.g., ipilimumab), an anti-PD1 antibody, an anti-PDL1 antibody, an anti-TIMP3 antibody, an anti-LAG3 antibody, an anti-B7H3 antibody, an anti-B7H4 antibody, or an anti-B7H6 antibody.

[0053] In particular, patients diagnosed with CMMRD or MSI leukemia / lymphoma according to the present invention can be treated with immunotherapy such as immune checkpoint blockade, including anti-CTLA4, anti-PD1, anti-PD-L1, alone or in combination, or anti-cancer vaccines based on tumor-specific antigens or dendritic cell vaccines.

[0054] Active specific immunotherapy typically involves the use of cancer vaccines.Cancer vaccines have been developed that contain whole cancer cells, parts of cancer cells, or one or more antigens derived from cancer cells.Cancer vaccines have been studied alone or in combination with one or more immune or chemotherapy agents in the treatment of several types of cancer, including melanoma, renal cancer, ovarian cancer, breast cancer, colorectal cancer, and lung cancer.Non-specific immunotherapy drugs are effective in combination with cancer vaccines to enhance the body's immune response.

[0055] Immunotherapeutic treatment may consist of adoptive immunotherapy, as described by Nicholas P. Restifo, Mark E. Dudley and Steven A. Rosenberg “Adoptive immunotherapy for cancer: harnessing the T cell response, Nature Reviews Immunology, Volume 12, April 2012). In adoptive immunotherapy, the subject's circulating or tumor-infiltrating lymphocytes are isolated in vitro, activated with lymphokines such as IL-2 or transduced with tumor necrosis genes, and then re-administered (Rosenberg et al., 1988; 1989). Most preferably, the lymphocytes activated are the subject's own cells, isolated earlier from a blood or tumor sample and activated (or "expanded") in vitro. This form of immunotherapy has resulted in regression of melanoma and renal cancer in some cases.

[0056] If it is concluded that the subject has a CMMRD cancer, the physician may choose to administer radiation therapy to the subject.

[0057] The term "radiotherapy agent" as used herein is intended to refer to, but is not limited to, any radiotherapy agent known to those skilled in the art to be effective in treating or ameliorating cancer. For example, the radiotherapy agent may be an agent such as those administered in brachytherapy or radionuclide therapy. Such methods may optionally further include administering one or more additional cancer therapies, such as, but not limited to, chemotherapy and / or another radiation therapy.

[0058] A kit or device of the present invention: A further object of the invention relates to a kit or device for carrying out the method of the invention, comprising means for extracting and sequencing DNA from a sample.

[0059] In some embodiments, the kit or device comprises at least one set of primers for each locus.

[0060] The present invention is further illustrated by the following figures and examples, which should not, however, be construed as limiting the scope of the present invention in any manner. [Brief description of the drawings]

[0061] [Figure 1A]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 1A-1]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 1B]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 1B-1]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 1C]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 1C-1]A and A-1) Working hypothesis: Microsatellite mutations are observed at mononucleotide microsatellites in tumor DNA of MMR-deficient (dMMR) / MSI colorectal cancers using standard PCR and fragment length size analysis. We hypothesized that PBC from CMMRD patients acquire ultra-low level microsatellite mutations (UL-MSI) even before cancer onset, and that such mutations can be detected using massively parallel sequencing. B and B-1) Principle of the algorithm used to detect MSI and UL-MSI in dMMR tumors and CMMRD PBC, respectively: The read counts of stutters based on the major allele of mononucleotide loci follow a log10 distribution. After determining the limiting regression parameters from MSS controls (i.e., the regression parameters closest to the MSI samples) and establishing an empirical standard model for each locus, the observed read counts are compared to the values ​​predicted by the model, and the differences are summed over all loci in each sample to derive the ms. score. C and C-1) Classification of samples in discovery and validation sets based on ms.score. The normalized ms.score of each sample is plotted for MSS controls, PBC from CMMRD patients, CMMRD LCL, and MSI CRC controls. The blue line identifies CMMRD cases common to the two studies. Error bars represent the first and third quartiles and the median of each distribution. Brackets indicate the p-value obtained by comparing each distribution with MSS controls using the Spearman correlation test (10000 permutations). MPS: massively parallel sequencing. [Figure 2A]Classification of samples tested in the two studies after ms.score determination using the full panel (number of loci per study shown). Dots represent each sample plotted after ms.score scaling. CMMRD dots identify samples common to both studies. In the discovery study (Panel A), as expected, MSI tumors had the highest ms.score, CMMRD LCLs had intermediate ms.score values, and CMMRD PBCs had similar levels of ms.score values. p-values ​​for distribution comparison are shown (Spearman correlation test, 10000 permutations). Error bars represent the distribution of the first and third quartiles and the median of each distribution. In the validation study (Panel B), cases showed systematically higher ms.scores compared to controls, confirming the benefit of this criterion for assessing UL-MSI in CMMRD PBC samples. [Figure 2B] Classification of samples tested in the two studies after ms.score determination using the full panel (number of loci per study shown). Dots represent each sample plotted after ms.score scaling. CMMRD dots identify samples common to both studies. In the discovery study (Panel A), as expected, MSI tumors had the highest ms.score, CMMRD LCLs had intermediate ms.score values, and CMMRD PBCs had similar levels of ms.score values. p-values ​​for distribution comparison are shown (Spearman correlation test, 10000 permutations). Error bars represent the distribution of the first and third quartiles and the median of each distribution. In the validation study (Panel B), cases showed systematically higher ms.scores compared to controls, confirming the benefit of this criterion for assessing UL-MSI in CMMRD PBC samples. [Figure 3A]Classification of samples as CMMRD and MSI in the two assays after ms.score determination using the full panel (number of loci per assay shown). A. The first assay is performed with 15 non-neoplastic MSS control samples, 27 CMMRD blood samples, and 4 MSI colon cancer. B. The second assay is performed with 10 non-neoplastic MSS control samples, 6 CMMRD samples, and 2 MSI colon cancer samples. [Figure 3B] Classification of samples as CMMRD and MSI in the two assays after ms.score determination using the full panel (number of loci per assay shown). A. The first assay is performed with 15 non-neoplastic MSS control samples, 27 CMMRD blood samples, and 4 MSI colon cancer. B. The second assay is performed with 10 non-neoplastic MSS control samples, 6 CMMRD samples, and 2 MSI colon cancer samples.

[0062] [Table 1]

[0063] Working Example: Materials and Methods Sequencing and data analysis After sequencing of the samples, the read count distribution was determined for all loci, and the ms. score was obtained by integrating the difference between the observed distribution of read counts of the test samples and the distribution of read counts predicted by a standard model derived from MSS controls (see Figure 1A and Figure 1B for a full explanation of the working hypotheses and the principles of the ms. score method). The ms. score was rescaled based on the highest ms. score of the MSS control subjects, such that control MSS cases do not exceed 1, but MSIs exceed 1. Read count distribution analysis and ms. score determination were performed using an R-based package. The distribution of ms. scores was compared between CMMRD confirmed patients and controls using a Spearman correlation test with 10,000 permutations (see Supplementary Materials and Methods for further details, and also Supplementary Tools for the scripts used to determine the ms. score).

[0064] Study population Eligible subjects included 16 patients already diagnosed with CMMRD (i.e., with biallelic deleterious germline mutations in one of the four major MMR genes, N = 11) or with a strong clinical suspicion of CMMRD (clinical score ≥ 3 according to a priori criteria from the C4 CMR Consortium, N = 5) (2). As MSS (non-MSI) controls, 34 MMR-proficient subjects without MMR germline defects were used. MSI controls consisted of colorectal cancer samples (CRC, N = 4) and lymphoblastoid cell lines (LCLs) (N = 7) obtained from CMMRD patients and previously shown to exhibit a distinct MSI phenotype after in vitro culture2. All patients gave written informed consent, and the Institutional Review Board / Ethics Committee of the participating institutions approved the study.

[0065] Mutation screening of MMR genes and other functional tests to aid in the diagnosis of CMMR All analyses were performed in clinically approved laboratories. Analysis of the MLH1, MSH2, and MSH6 genes was performed in separate laboratories, whereas PMS2 analysis was performed at the Rouen, Lille, or Innsbruck laboratories as previously described. LCLs were obtained after standard Epstein-Barr virus infection. Ex vivo MSI analysis and methylation resistance assays were performed with LCLs as previously described (6).

[0066] Study design The above samples (16 confirmed or clinically highly suspected CMMRD cases, 11 MSI controls, and 34 MSS controls) were distributed into two overlapping sets: a discovery set (14 controls, including 7 CMMRD LCL, 4 MSI CRC, and 3 MSS controls; 8 confirmed or clinically highly suspected CMMRD cases) and a validation set (31 MSS healthy controls; 14 confirmed or clinically highly suspected CMMRD cases, 6 of which were also included in the discovery set). The two sets were analyzed separately by massively parallel sequencing using two overlapping panels of probes covering mononucleotide repeats of 6-27 base pairs in length (2586 regions of interest (ROIs) and 1187 ROIs for the discovery and validation studies, respectively, with 395 ROIs common to the two sets). The first set was designed to allow a theoretical coverage depth of 10,000× using sequencing settings with ROIs already discovered and validated for MSI analysis (7,8). For the second study, we included 48 DNAs because we wanted a theoretical coverage depth of 6,000× using probes targeting loci obtained in the same study as the first set. A panel of only 3 MSS cases was used in the discovery study because it was sufficient to build a working algorithm for identifying MSI / UL-MSI. At least 30 MSS cases were considered sufficient to take into account polymorphisms and to obtain accurate models of the loci analyzed in the validation study (32 MSS DNAs were initially processed, 1 failed library QC). The 16 initially processed CMMRD cases were randomly drawn from the consortium database to avoid selection bias (16 cases initially confirmed or suspected CMMRD, 2 failed library QC).

[0067] Massively parallel sequencing of the MNR locus Samples were sequenced and analyzed separately. After DNA sonication and quality control, barcoded DNA libraries were obtained using Nimblegen SeqCap solution, pooled, and target fragments were captured using Nimblegen's SeqCap EZ Choice library kit. Sequencing was performed on a NextSeq 500 (Illumina). Reads were trimmed and examined for quality and coverage depth. The mean coverage depth per sample ranged from 1778 to 6140, with an average of 242 loci not covered in the discovery study. In the second study, the mean coverage depth per sample ranged from 235 to 5349, with 33 or fewer probes not covered in all but one sample. Overall, this second assay yielded lower quality reads with higher levels of PCR / sequencing duplicates and lower uniformity of coverage across loci when considering samples individually and across samples' global mean coverage. Additionally, one sample (C01.2) had a lower mean coverage (82x) and a higher number of uncovered loci (n=485), but was tested similarly to all other samples to evaluate the classification algorithm in the context of low numbers of qualified reads.

[0068] Fastq files were processed for global alignment against the hg19 reference genome, followed by more precise local alignment of the mononucleotide repeat containing reads using the GATK IndelRealigner tool to minimize misalignments. Counts of reads with integral coverage of the target mononucleotide repeat were obtained using a modified version of MSIsensor (11) and further processed to assess the presence of aberrant mononucleotide repeat sequences in the samples.

[0069] Identifying analytical readouts to classify MSI / UL-MSI cases For each sample, the distribution per locus was normalized to the counts of the major allele and log-transformed: for each MSS control locus, a linear regression model was applied. The limiting regression parameters (i.e., the minimum slope, the maximum y-intercept, and the correlation coefficient r) were retained to create a locus-limiting model, which could therefore be considered as a background model for the distribution of stutters based on the major allele. Only repeats with the same nucleotide length as the reference genome sequence were retained. After removing polymorphic alleles (considered if the frequency of another proximal peak was greater than 0.7) and artifact counts (reads containing noise and / or interrupted repeats), the model was used to predict the log value of the stutter read counts for each major allele for standard MSS samples. Due to the often shortened mononucleotide repeats in MSI, a positive difference between the observed and predicted read counts is observed in MSI samples, but not in MSS. The ms. score per locus was obtained by integrating the difference between the observed and predicted read counts. The ms.scores per locus were then summed to give the sample ms.score, which was used as a summary measure of the accumulated changes in all repeats analyzed in a particular sample. The ms.scores in each study were then normalized such that the ms.score of MSS controls did not exceed 1: thus, test samples must show a value above 1 to be classified as MSI / UL-MSI.

[0070] In the discovery study, three MSS control samples were used to generate standardized regression models for each locus in the panel and predicted log-transformed read counts for the MSS standards.

[0071] In the second study, 31 MSS controls available after sequencing were used to generate standardized regression models and predictors of log-transformed read counts for the MSS standards.

[0072] Optimized probe sets: Application of molecular testing to detect confirmed and suspected CMMRD individuals In two studies, we tried to improve the ms. score determination by limiting the number of ROIs. Two parameters were used to select the most informative probes: the average coverage depth per locus across samples and the distribution of ms. score values. The average coverage depth for each locus, averaged across the 22 samples in the first study, was greater than 2000 reads for 88% of all loci analyzed. Selection of loci covering 1000-5000 reads with each selection 1000× window did not significantly change the relative ms. score when compared between different sample classes (data not shown), but the absolute ms. score decreased when the number of loci incorporated was reduced. This was expected, since a very small number of loci results in a significant loss of information and poor performance (low sensitivity and specificity). The size of the mononucleotide repeat could be a useful parameter for probe selection, but no difference was observed for repeats of at least 8 bp (data not shown).

[0073] When only loci with raw ms. scores above a predefined threshold (i.e., 0.1) for a minimum number of samples (i.e., n > 16) were retained, only 118 loci were needed to discriminate MSS controls from CMMRD cases or MSI positive controls as accurately as the full panel. Using this subset of loci, ms. scores for MSS controls ranged from 0 to 1 (mean = 0.47), whereas ms. scores for CMMRD PBC ranged from 12.77 to 30.74 (mean = 20.21) and 13.98 to 16.16 (mean = 15.07) for confirmed and suspected CMMRD cases, respectively (MSS controls vs all CMMRD PBC, P = 2.4 × 10-5; data not shown).

[0074] In the case-control study, the mean coverage depth for each locus averaged over 45 samples was greater than 2000 reads for 89% of all loci analyzed. Selection of loci covering 1000–5000 reads by a window of 1000× each selection did not significantly change the relative values ​​of the ms.score when compared between different sample classes (Figure 3A), although the extreme coverage categories (i.e., <1000× and ≥5000×) showed lower performance, possibly due to accumulation of read artifacts and / or PCR / sequencing overlap levels. The size of the mononucleotide repeat did not significantly affect the classification of the samples tested, as expected from the preceding results (data not shown).

[0075] When only loci with raw ms. scores above the same threshold (i.e., 0.1) for a minimum number of samples (i.e., n > 5) were retained, as few as 18 loci were able to discriminate MSS controls from CMMRD cases as accurately as the full panel. The ms. scores for MSS controls ranged from 0 to 1 (mean = 0.49), whereas the ms. scores for CMMRD PBC ranged from 1.74 to 4.30 (mean = 2.77) and 1.62 to 4.13 (mean = 2.81) for confirmed and suspected CMMRD cases, respectively (MSS controls vs. all CMMRD PBC, P = 2.1 × 10-7) (data not shown).

[0076] statistical analysis Read count distribution analysis and ms.score determination were performed using an R-based package. Comparisons between ms.score distributions of samples and controls were calculated using a one-tailed Welch two-sample test.

[0077] Scripts written to perform the analysis (bash and R) were developed in an Ubuntu 16.04 environment and are available in the supplemental tools.

[0078] result Discovery Set: Proof-of-Concept Studies To test our working hypothesis, summarized in Figure 1A, we first investigated whether UL-MSI could be detected by massively parallel sequencing using ms.score in PBCs from subjects with confirmed CMMRD (N=6) when compared to three MSS and MSI controls included in the discovery set (four MSI CRC samples and seven CMMRD LCLs). The ms.score values ​​for MSS controls ranged from 0.56 to 1, with a mean of 0.74. The ms.scores for CMMRD LCLs ranged from 1.40 to 2.82 (mean=1.96), whereas for CMMRD PBCs, the ms.scores for confirmed cases ranged from 1.13 to 2.89 (mean=1.67), thus indicating a sensitivity of 100% (Figure 2A). The ms.scores for suspected CMMRD cases ranged from 1.07 to 1.11 (mean 1.09). Comparison of the distribution of ms. scores between the groups showed significant differences between MSS and MSI controls (CRC, P = 0.029; CMMRD LCL, P = 0.0082), but also between PBC with confirmed CMMRD (P = 0.012). Interestingly, UL-MSI was also detected in suspected CMMRD cases, confirming the diagnosis already made by functional tests and high clinical scores. The key inputs of the algorithm were the number of loci and the coverage depth (data not shown). For microsatellites of 8 bp or more in length, significant differences were observed between ms. scores of samples from confirmed CMMRD and MSS controls (data not shown).

[0079] Validation set: case-control study In accordance with our findings that UL-MSI is detected in microsatellites ≥8 bp in length regardless of locus, a second series of 45 samples was sequenced using a nearly completely different panel of microsatellites ≥8 bp in length and containing only 395 loci in common with the first study. In this second series of CMMRD cases (9 confirmed, 5 suspected) and MSS controls (healthy individuals, N=31), the ms. scores of MSS controls ranged from 0 to 1 (mean 0.49) compared to 1.19 to 4.13 (mean=2.36) and 1.11 to 3.84 (mean=2.31) for confirmed and suspected CMMRD PBC, respectively (Figure 2B). Comparison of ms. score distributions between MSS and confirmed CMMRD individuals showed a statistically significant difference (P<2.2×10 -16 ), again with 100% sensitivity, able to correctly distinguish CMMRD samples from MSS controls. As in previous studies, all suspected CMMRD cases confirmed the previously diagnosed CMMRD status. Again, key inputs to the algorithm were the number of loci and coverage depth (data not shown). As expected, the difference in ms. score between confirmed CMMRD and MSS samples was significant for all selected microsatellites (length ≥ 8 bp; see above and data not shown).

[0080] Probes optimized for detection of confirmed and suspected CMMRD individuals Finally, we aimed to limit the number of probes in the panel required to distinguish CMMRD subjects from healthy MSS controls. By applying a threshold filter to the distribution of this parameter, we obtained a subset of probes with higher discrimination. In the first panel used in the proof-of-concept study, only 118 loci were required to distinguish MSS from CMMRD or MSI positive controls as accurately as the full panel. Using this subset of loci, MSS controls had ms. scores in the range of 0-1 (mean=0.47) compared to 12.77-30.74 (mean=20.21) and 13.98-16.16 (mean=15.07) for confirmed and suspected CMMRD cases, respectively (MSS controls vs. confirmed CMMRD PBC, P=0.007; see Figure 1C). A second panel used in the case-control study and operated with the same two parameters as the discovery study was able to discriminate MSS from confirmed and suspected CMMRD cases as accurately as the full panel, with only 18 loci. MSS controls had ms. scores in the range 0-1 (mean=0.49), compared with 1.74-4.30 (mean=2.77) and 1.62-4.13 (mean=2.81) for confirmed and suspected CMMRD cases, respectively (MSS controls vs. confirmed CMMRD PBC, P<2.2×10 -16 )(Figure 1C-1).

[0081] Classification of CMMRS and MSI tumor samples in the two assays To confirm the ability of the method of the present invention to correctly classify CMMRD and generally MSI tumor samples, two new assays were performed. The first assay used 15 non-tumor MSS control samples, 27 CMMRD blood samples, and 4 MSI colon cancer samples, and the second assay used 10 non-tumor MSS control samples, 6 CMMRD blood samples, and 2 MSI colon cancer samples. These two assays confirmed the ability of the proposed method to correctly classify CMMRD and generally MSI tumor samples. The sensitivity and specificity of both assays were 100% (Figure 3A and B, respectively).

[0082] Consideration MSI testing of tumor DNA has recently emerged as important for identifying patients with metastatic cancer who may benefit from immune checkpoint inhibitors. 9 Here, we demonstrate that MSI testing of germline DNA can also be used to detect key predisposing factors for tumor development in CMMRD patients, for whom successful treatment with immune checkpoint inhibitors has recently been reported. 4、5 The test proposed here for screening of CMMRD using PBC is feasible and shows 100% sensitivity and specificity in our experiments (Table 1). By implementing this method, patients with UL-MSI and thus suffering from CMMRD syndrome can be more easily identified in terms of three important parameters, namely average coverage depth ranging from 1000× to 5000× and at least 100 target mononucleotide repeats of 8 base pairs or more. Importantly, this test is much more rapid than the one proposed recently by the inventors and which requires culturing LCL from the patient. 6 Moreover, it has much higher sensitivity and specificity than previous approaches developed to identify germline MSI from patient PBC testing. 10 (Table 1). We recommended its use for children with CMMRD spectrum tumors to allow rapid diagnosis of the syndrome and before other tumors develop later in life.

[0083] References: Throughout this specification various references describe the state of the art to which this invention pertains, the disclosures of which are incorporated by reference into this disclosure. [Table 2]

Claims

1. A method for providing data for diagnosing constitutional mismatch repair deficient (CMMRD) cancer or microsatellite instability (MSI) leukemia / lymphoma in a patient in need thereof, the method comprising: i) extracting DNA from a sample obtained from said patient; ii) sequencing the number of repeat sequences having a length of (x) nucleic acids from the DNA of said patient, where the term "repeat" refers to the number of nucleic acids repeated for a particular locus; iii) repeating steps i) and ii) with at least one control subject with a microsatellite stable cancer (a microsatellite stable (MSS) control subject); iv) calculating the log10 transformation of the read counts per locus for the patient and the MSS control subjects, and performing limit regression for each repeat obtained from the MSS control subjects; v) a compound of the formula: 【Chemistry 4】 (where N = maximum number of repeat sequences sequenced; n = number of repeat sequences considered; Δ = number of reads (sample of patient in need) - number of reads (limit regression from MSS control subjects), where the term "number of reads" refers to the number of times a repeat sequence having a length of (x) nucleic acids for a particular locus is repeated.) calculating an ms. score by processing the vi) mathematically comparing the ms. score obtained in the patient in need thereof with the ms. score of the MSS control subject; and vii) providing data to conclude that the patient in need thereof has a CMMRD cancer or MSI leukemia / lymphoma if the ms. score of the patient in need thereof is greater than the ms. score of the MSS control subject; The method includes:

2. The method of claim 1 , wherein the sequencing is performed by a second generation sequencing method.

3. The method of claim 1, wherein the sequencing is performed for a number of loci between 10 and 10,000.

4. The method of claim 1, wherein the number of reads is between 500 and 4000.

5. The method described in claim 4, wherein the number of leads is 1,000 to 4,000.

6. The method according to claim 1, wherein the length (x) of the nucleic acid repeat is 8 to 30.

7. The method of claim 6, wherein the repeat length (x) of the nucleic acid is 8 to 14.

8. 2. The method of claim 1, wherein the CMMRD cancer is CMMRD colorectal cancer.

9. 2. The method of claim 1, wherein said at least one MSS control subject varies from 1 to 30.

10. The method of claims 1 to 7, wherein the DNA is germline DNA.

Citation Information

Patent Citations

  • Microsatellite biomarker combination, detection kit and use thereof

    CN109182525A

  • Dominant-negative HSP110 mutants, and their use in cancer prediction and treatment.

    JP2014512174A

  • Compositions and methods for determining endometrial cancer prognosis

    WO2016127067A1